Alnylam Pharmaceuticals (ALNY) Change in Receivables (2009 - 2026)

Alnylam Pharmaceuticals has reported Change in Receivables for 18 years, with the latest figure at $110.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 1385.35% year-over-year to $110.4 million; the trailing twelve-month figure through Mar 2026 stood at $463.0 million (up 390.44% YoY), and the FY2025 full-year result was $360.0 million, up 315.9% from the prior year.
• Change in Receivables for Q1 2026 stood at $110.4 million, up from -$184.2 million in the prior quarter.
• The five-year high for Change in Receivables was $399.9 million in Q3 2025, with the low at -$184.2 million in Q4 2025.
• Historically, Change in Receivables has averaged $40.6 million across 5 years, with a median of $7.4 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Receivables plunged 470.68% — and 2025, when it jumped 1913.17%.
• Alnylam Pharmaceuticals' Change in Receivables stood at $53.3 million in 2022, then slumped by 107.26% to -$3.9 million in 2023, then jumped by 1638.07% to $59.5 million in 2024, then plunged by 409.62% to -$184.2 million in 2025, then jumped by 159.93% to $110.4 million in 2026.
• The last three Change in Receivables figures came in at $110.4 million (Q1 2026), -$184.2 million (Q4 2025), and $399.9 million (Q3 2025), per Business Quant data.